Literature DB >> 11535525

Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection.

Y Kasahara1, A Yachie, K Takei, C Kanegane, K Okada, K Ohta, H Seki, N Igarashi, K Maruhashi, K Katayama, E Katoh, G Terao, Y Sakiyama, S Koizumi.   

Abstract

Unusual Epstein-Barr virus (EBV) infection into T or natural killer cells plays a pivotal role in the pathogenesis of acute EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and chronic active EBV infection (CAEBV). The precise frequency and localization of EBV genome in lymphocyte subpopulations especially within T-cell subpopulations are unclear in these EBV-related disorders. This study analyzed the frequency of EBV-infected cells in circulating lymphocyte subpopulations from 4 patients with acute EBV-HLH and 4 with CAEBV. EBV- encoded small RNA-1 in situ hybridization examination of peripheral blood lymphocytes showed a significantly higher frequency of EBV-infected cells of 1.0% to 13.4% in EBV-HLH and 1.6% to 25.6% in CAEBV, respectively. The patterns of EBV infection in lymphocyte subpopulations were quite different between acute EBV-HLH and CAEBV. EBV infection was predominant in CD8(+) T cells in all EBV-HLH patients, whereas the dominant EBV-infected cell populations were non-CD8(+) lymphocyte subpopulations in CAEBV patients. Phenotypical analysis revealed that EBV-infected cell populations from both EBV-HLH and CAEBV were activated. There was no predominance of any EBV substrain of latent membrane protein-1, EBV-associated nuclear antigen (EBNA)-1, and EBNA-2 genes between the 2 abnormal EBV-associated disorders, and self-limited acute infectious mononucleosis. These results showing differential virus-cell interactions between acute EBV-HLH and CAEBV indicated different pathogenic mechanisms against EBV infection between the 2 EBV-associated diseases, which accounts for the difference in clinical manifestations between the 2 diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535525     DOI: 10.1182/blood.v98.6.1882

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis.

Authors:  Li Fu; Jingshi Wang; Na Wei; Lin Wu; Yini Wang; Wenqiu Huang; Jia Zhang; Jinli Liu; Zhao Wang
Journal:  Int J Hematol       Date:  2016-07-18       Impact factor: 2.490

2.  Fatal primary Epstein-Barr virus infection due to clonal CD8+ T-lymphocyte proliferation in an immunocompetent adult.

Authors:  Naoko Satoh; Tadashi Koike; Hidekichi Takato; Masahiro Fujiwara; Iwao Emura; Hirokazu Kaneganed
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 3.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

4.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

5.  Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection.

Authors:  S Toyabe; W Harada; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

6.  Cardiovascular complications associated with chronic active Epstein-Barr virus infection.

Authors:  Jun Muneuchi; Shouichi Ohga; Masataka Ishimura; Kazuyuki Ikeda; Kenichiro Yamaguchi; Akihiko Nomura; Hidetoshi Takada; Yasunobu Abe; Toshiro Hara
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

7.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

Authors:  B Hügle; P Suchowerskyj; H Hellebrand; B Adler; M Borte; U Sack; U Schulte Overberg-Schmidt; N Strnad; J Otto; A Meindl; V Schuster
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

9.  Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3.

Authors:  Dai Iwakiri; Li Zhou; Mrinal Samanta; Misako Matsumoto; Takashi Ebihara; Tsukasa Seya; Shosuke Imai; Mikiya Fujieda; Keisei Kawa; Kenzo Takada
Journal:  J Exp Med       Date:  2009-08-31       Impact factor: 14.307

10.  Severe chronic active EBV infection in an adult patient: case report.

Authors:  Sang-Yoon Ha; Chul-Won Chung; Young H Ko
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.